Regulatory Requirements of Biosimilars: Drug Development in Ophthalmology, Part 1.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

Journal of Ocular Pharmacology and Therapeutics Pub Date : 2024-11-01 Epub Date: 2024-11-04 DOI:10.1089/jop.2024.0151

Cheryl L Rowe-Rendleman

引用次数: 0

查看原文本刊更多论文

生物仿制药的监管要求：眼科药物开发，第 1 部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Ocular Pharmacology and Therapeutics 医学-眼科学

CiteScore

4.60

自引率

4.30%

发文量

审稿时长

1 months

期刊介绍： Journal of Ocular Pharmacology and Therapeutics is the only peer-reviewed journal that combines the fields of ophthalmology and pharmacology to enable optimal treatment and prevention of ocular diseases and disorders. The Journal delivers the latest discoveries in the pharmacokinetics and pharmacodynamics of therapeutics for the treatment of ophthalmic disorders. Journal of Ocular Pharmacology and Therapeutics coverage includes: Glaucoma Cataracts Retinal degeneration Ocular infection, trauma, and toxicology Ocular drug delivery and biotransformation Ocular pharmacotherapy/clinical trials Ocular inflammatory and immune disorders Gene and cell-based therapies Ocular metabolic disorders Ocular ischemia and blood flow Proliferative disorders of the eye Eyes on Drug Discovery - written by Gary D. Novack, PhD, featuring the latest updates on drug and device pipeline developments as well as policy/regulatory changes by the FDA.